文献速递前列腺癌

德国、英国和美国局限性及晚期前列腺癌患者的大规模数字调查

A Large-scale Digital Survey of Patients with Localized and Advanced Prostate Cancer in Germany, the UK, and the USA.
PubMed 文献 · Eur Urol Oncol · 2025-04-07

调查评估了 demographics、诊断、治疗史、治疗感知、医疗团队参与及健康相关生活质量(HRQoL)。结果显示三国在诊断、治疗模式和参与专科医生方面存在异同,治疗满意度总体较高但随时间下降,晚期疾病和多种合并症是HRQoL较差的预测因素。

要点

  • 德国和美国常规筛查诊断更常见,英国较少。
  • 局限性前列腺癌在德国和美国最常见治疗为前列腺切除术,英国为放疗。
  • 晚期疾病和多种合并症是健康相关生活质量较差的预测因素。

核心结论

  • 三国前列腺癌患者旅程存在差异,HRQoL无国别差异但受晚期疾病状态和合并症负担影响。
  • 共同的诊断、治疗实践和指南方法可能改善结局。

研究设计与样本

  • 大规模数字调查,由多利益相关方小组设计和解读。
  • 使用描述性统计,并以简单线性回归和多元线性回归分析人口学和临床因素对HRQoL的影响。

主要发现

  • 德国和美国常规筛查诊断比英国更常见。
  • 局限性疾病最常见治疗:德国和美国为前列腺切除术,英国为放疗。
  • 晚期疾病最常见治疗在三国均为激素治疗。
  • 治疗满意度总体较高但随时间下降。
  • 未接受积极治疗的患者对治疗类型及其对HRQoL的影响通常持负面看法。

临床怎么用

  • 临床应关注晚期疾病和合并症负担对HRQoL的影响。
  • 未接受积极治疗的患者需加强治疗预期和HRQoL影响的沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We conducted a prostate cancer (PC) survey to provide a better understanding of the patient journey, expectations, and attitudes related to treatment. METHODS: This large-scale digital survey of patients with localized or advanced PC from Germany, the UK, and the USA assessed their demographics, diagnosis, treatment history, perception of therapy, medical care team involvement, and health-related quality of life (HRQoL). The survey was designed and interpreted by a large multistakeholder group. Descriptive statistics were primarily used. Univariate and multivariate analyses of the impact on HRQoL by demographic and clinical factors, including disease and treatment history, were examined using simple and multiple linear regression analyses, respectively. KEY FINDINGS AND LIMITATIONS: Overall, 15 824 participants completed the survey and 14 812 reported their disease status (79.6% had localized and 20.4% had advanced PC). Across the three countries, there were similarities and differences in diagnosis, treatment patterns, and medical specialists involved. Diagnosis by routine screening was more common in Germany and the USA than in the UK. For localized disease, the most common treatment was prostatectomy in Germany and the USA, and radiotherapy in the UK. Hormone therapy was the most common treatment for advanced disease across countries. Overall, treatment satisfaction was high but decreased over time. Patients not on active treatment generally had negative perceptions of treatment types and their impact on HRQoL. Advanced disease and multiple comorbidities were identified as the predictors of worse HRQoL. CONCLUSIONS AND CLINICAL IMPLICATIONS: This study highlights differences in the PC patient journey in Germany, the UK, and the USA. HRQoL did not differ between countries but was affected by advanced disease status and comorbidity burden. A common approach to PC diagnosis, treatment practices, and guidelines could improve outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. O'Sullivan JM, Gonzalez BD, Gudenkauf LM, et al. A Large-scale Digital Survey of Patients with Localized and Advanced Prostate Cancer in Germany, the UK, and the USA. Eur Urol Oncol. 2025. PMID: 40199644. doi:10.1016/j.euo.2025.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。